Differential Effect of Intraperitoneal Albendazole and Paclitaxel on Ascites Formation and Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cell-Bearing Athymic Nude Mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objectives: The purposes of our study were to evaluate the effect of intraperitoneal albendazole on tumor growth, ascites formation, and vascular endothelial growth factor (VEGF) mRNA expression, and to assess the synergistic effect of paclitaxel in OVCAR-3-bearing nude mice. Methods: In all, 4 groups of mice were injected intraperitoneally with weekly albendazole (450 mg/kg per week), paclitaxel (30 mg/kg per week), albendazole plus paclitaxel, or normal saline for 4 weeks. Results: Ascitic fluid accumulation (2.47, 2.65, 2.88, and 5.90 mL, respectively) and in ascitic VEGF levels were significantly reduced in the 3 treatment groups compared to the control group (170.83, 229.16, 267, and 1625 pg/mL, respectively). However, complete tumor suppression was more prominent in the paclitaxel group, and VEGF mRNA expression was more strongly inhibited in the albendazole group (P < .05). No synergistic effect of albendazole and paclitaxel was observed. Conclusion: We demonstrated a differential effect of albendazole and paclitaxel in a xenograft model of ovarian carcinoma; albendazole suppressed ascites formation by inhibiting VEGF secretion, and paclitaxel exerted its effects by direct cytotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albendazole: a review of anthelmintic efficacy and safety in humans
HORTON, J. (2000) · Parasitology · doi:10.1017/s0031182000007290 · Cited by 386
In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole
Pourgholami, M. H., Woon, L., Almajd, R., Akhter, J., Bowery, P., & Morris, D. L. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00382-2 · Cited by 139
Hossein Pourgholami, M., Yan Cai, Z., Lu, Y., Wang, L., & Lawson Morris, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1181 · Cited by 100 · cited 4×
“Therefore, small tumors that obtain nutrients by simple diffusion or tumors with their own vasculature are able to survive, but further growth is restricted, and therefore, the tumors remain small.(18,21) In short, albendazole exerts its therapeutic effect mainly by inhibiting VEGF expression and neovascularization.”
BackgroundInfluential
Cited by
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55
Nanoformulations of Albendazole As Effective Anticancer and Antiparasite Agents
Movahedi, F., Li, L., Gu, W., & Xu, Z. P. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0102 · Cited by 34
Metadata
- Authors
- Choi, E.-K., Kim, S.-W., Nam, E.-J., Paek, J., Yim, G.-W., Kang, M.-H., & Kim, Y.-T.
- Venue
- Reproductive Sciences
- Published
- 2011-08
- Volume
- 18
- Issue
- 8
- Pages
- 763-771
- ISSN
- 1933-7191 (ISSN-L)
- 1933-7205
- OpenAlex
- W2046833247
- Cited by
- 15
- References
- 3
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential Effect of Intraperitoneal Albendazole and Paclitaxel on Ascites Formation and Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cell-Bearing Athymic Nude Mice. https://app.cochat.ai/papers/10.1177/1933719111398142
- The paper
- Choi, E.-K., Kim, S.-W., Nam, E.-J., Paek, J., Yim, G.-W., Kang, M.-H., & Kim, Y.-T. (2011). Differential Effect of Intraperitoneal Albendazole and Paclitaxel on Ascites Formation and Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cell-Bearing Athymic Nude Mice. Reproductive Sciences. https://doi.org/10.1177/1933719111398142
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.